Thursday, July 2, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Jul 1, 2026
Biotechs ‘in better position to avoid workforce reductions’ as layoffs continue to ease in Q2’26
background ▾
- •Biopharma layoff announcements in Q2 2026 fell to 17 companies versus 64 in Q2 2025, representing a 73% decline from peak crisis levels and indicating stabilization in the sector
- •Improving M&A activity, reopening IPO financing, and stable macroeconomic conditions are cited as primary drivers of reduced workforce pressure, though individual asset failures and regulatory rejections still trigger layoffs
- •Monitor whether large pharma restructurings (BioNTech 1,860 cuts; Takeda 4,500 cuts) signal renewed pressure or are one-time strategic realignments, and track whether AI-driven productivity claims translate to actual headcount reductions in H2 2026
Sangamo TherapeuticsEli LillyAstellas Pharma
→ Read original articlePolicy•STAT News•Jul 2, 2026
Opinion: CDC leadership continues to try manufacture a scientific debate on vaccines where none exists
background ▾
- •CDC leadership under Jay Bhattacharya is actively questioning and restricting established vaccine effectiveness measurement methodologies and publishing protocols, signaling potential shifts in how vaccine surveillance and policy recommendations will be conducted
- •The test-negative design (TND), a foundational epidemiological tool used for decades across flu, Covid, and RSV vaccine monitoring, is now under official challenge despite its widespread scientific validation and real-world utility
- •Watch for: future publication decisions on blocked CDC vaccine effectiveness studies, implementation of revised ACIP charter language on vaccine alternatives, and whether these methodological disputes translate into changes in vaccine recommendations or surveillance practices
Covid-19 vaccinesInfluenza vaccinesRSV vaccines
→ Read original articlePolicy•STAT News•Jul 2, 2026
The new presidential fitness test is a positive step, not the solution, experts say
background ▾
- •The presidential fitness test has been revived as a centerpiece of HHS youth health strategy, but academic experts warn it is a measurement tool, not an intervention—and may be counterproductive if it generates negative childhood memories around physical activity
Policy•STAT News•Jul 2, 2026
Opinion: Teens are turning to chatbots for mental health help. We need rules to keep them safe
background ▾
- •AI chatbot adoption for mental health among teens jumped 40% year-over-year to reach 1 in 5 adolescents, representing millions of young users in an unregulated landscape.
- •Multiple lawsuits allege AI chatbots contributed to teen suicides; Florida's attorney general is investigating ChatGPT interactions preceding a 2025 mass shooting, and OpenAI apologized for failing to alert authorities about a banned account linked to a school shooter.
- •Proposed regulatory framework distinguishes between affective/companionship bots (candidate for outright bans to prevent parasocial dependency) and clinical-positioned bots (requiring pre-market clinical trials and independent safety validation before pediatric deployment).
OpenAI
→ Read original articlePolicy•KFF•Jul 2, 2026
Overview of President Trump’s Executive Actions Impacting LGBTQ+ Health
background ▾
- •Executive orders rescind Biden-era nondiscrimination and health equity protections for LGBTQ+ individuals, potentially reducing access to care and federal health program coverage for gender-affirming treatments
- •New executive order defines sex as immutable binary classification and removes legal recognition of gender identity, directing HHS to issue guidance within 30 days that could affect healthcare delivery, insurance coverage, and clinical practice standards
- •Litigation and regulatory implementation of these orders is ongoing—watch for challenges in federal courts, state-level counteractions, and how HHS guidance affects Medicare/Medicaid coverage policies and pharmaceutical treatment access
Market Access
Market Access•Fierce Biotech•Jul 1, 2026
Ipsen gets the Memo, penning €700M deal to buy rare disease biotech for clinical-stage asset
background ▾
- •Potravitug is a first-in-class asset addressing an unmet medical need in BK polyomavirus-associated nephropathy with FDA fast-track designation and recent phase 2 data supporting nephropathy resolution in kidney transplant recipients
- •Ipsen's dual acquisition strategy (Memo + Kartos in 3 days for ~$900M total upfront) signals aggressive pipeline expansion across rare disease, oncology, and neuroscience with emphasis on clinical-stage assets de-risked by early efficacy signals
- •Monitor potravitug's pivotal phase 2/3 trial initiation and regulatory pathway; assess commercial viability of a niche indication in kidney transplantation and Ipsen's ability to execute rapid integration post-acquisition
IpsenMemo TherapeuticsCSLpotravitugfidrisertibIqirvo
→ Read original articleMarket Access•Fierce Biotech•Jul 2, 2026
Insilico keeps partnership sprint apace in $600M biobucks collab with Takeda
background ▾
- •Insilico has secured $6.238 billion in total biobucks deal value across four major pharma partners in under 18 months, establishing itself as the dominant AI drug discovery platform vendor to large pharma.
- •The company claims 31 developmental candidates in its pipeline (3 in Phase 2, 8 in Phase 1) discovered in 9-18 months, faster than traditional methods, but clinical validation of this speed advantage is still emerging.
- •Monitor whether Takeda and other partners can translate Insilico's rapid discovery into clinical candidates that successfully advance through trials—the real test is late-stage efficacy and regulatory approval, not discovery speed alone.
Insilico MedicineTakedaEli Lilly
→ Read original articleMarket Access•Fierce Biotech•Jul 1, 2026
Zimmer Biomet buys non-drug pain relief system from Pacira for up to $140M
background ▾
- •Pacira divests iovera device to focus its portfolio on biopharmaceuticals (Exparel, Zilretta, PCRX-201 gene therapy), signaling a deliberate shift away from medtech commercialization.
- •Zimmer Biomet gains an FDA-cleared device with established market presence, leveraging its superior orthopedic device distribution and scale to expand patient access globally.
- •Monitor whether Zimmer successfully commercializes iovera at scale and whether the spasticity program collaboration yields regulatory approvals.
Pacira BioSciencesZimmer BiometioveraExparelZilretta
→ Read original articleMarket Access•Endpoints News•Jul 1, 2026
BridgeBio adds $1B as it prepares three more drug launches
background ▾
- •BridgeBio secured $1B in preferred equity financing to support three imminent drug launches
- •The capital infusion indicates the company is transitioning from development-stage to commercial-stage operations with multiple candidates approaching market entry
BridgeBio Pharma
→ Read original articleMarket Access•Endpoints News•Jul 1, 2026
Ipsen to scoop up Memo Therapeutics and its kidney infection drug
background ▾
- •Ipsen acquires Memo Therapeutics to add a kidney infection drug candidate to its infectious disease portfolio
- •This is Ipsen's second major deal announcement within one week, signaling aggressive portfolio expansion strategy
IpsenMemo Therapeutics
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Jul 1, 2026
Merck halts ph. 2 Alzheimer’s trial after Neuphoria small molecule underwhelms
background ▾
- •MK-1167 failed to meet efficacy thresholds in interim phase 2 analysis despite no safety concerns, halting development of Neuphoria's alpha-7 PAM for Alzheimer's disease
- •Neuphoria faces compounding challenges after BNC210 phase 3 failure in social anxiety (October 2024) and a failed acquisition attempt, with only a Scancell Holdings merger proposal under consideration
- •Merck's Alzheimer's pipeline is now heavily dependent on MK-2214 (tau antibody, phase 2 through 2029), leaving significant execution risk in a competitive disease area
Merck & Co.Neuphoria TherapeuticsBionomicsMK-1167MK-2214BNC210
→ Read original articleClinical Trials•STAT News•Jul 1, 2026
Statins and blood pressure drugs changing health risks of obesity, study suggests
background ▾
- •By 2024, adults aged 60–70 with obesity achieved blood pressure and LDL cholesterol levels equal to or lower than normal-BMI peers, representing a dramatic shift from historical cardiovascular risk patterns since 1990.
- •Expanded use of inexpensive generic statins and blood pressure medications (costing ~$100/year) among people with obesity drove the improvement; 70–72% of overweight/obese older adults used these drugs versus 40–48% of normal-BMI peers.
- •Young adults under 40 with obesity remain at high metabolic risk due to underscreening and undertreatment, representing a critical prevention gap that requires urgent clinical and policy attention.
statinsblood pressure medications
→ Read original articleClinical Trials•Endpoints News•Jul 1, 2026
92Bio revives a T cell engager it had transferred to Amgen
background ▾
- •92Bio is reactivating a T cell engager originally developed internally but transferred to Amgen, signaling potential program return or licensing reversal
- •The revival suggests Amgen may have deprioritized this asset, creating an opportunity for the smaller biotech to advance it
92BioAmgen
→ Read original articleClinical Trials•Endpoints News•Jul 1, 2026
Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data
background ▾
- •Angitia abandoned Phase 3 development of AGA111 in degenerative disc disease, signaling clinical or commercial challenges in this indication
- •Abivax is leveraging colitis trial data to support an $800M+ company valuation, indicating potential market enthusiasm for this program
- •Limited disclosure of clinical details raises questions about efficacy/safety drivers behind both decisions
Angitia BiopharmaceuticalsAbivaxAGA111
→ Read original article